Caroline Muren
New York University(US)
Publications by Year
Research Areas
Immunotherapy and Immune Responses, vaccines and immunoinformatics approaches, Immune Response and Inflammation, RNA Interference and Gene Delivery, Monoclonal and Polyclonal Antibodies Research
Most-Cited Works
- → Resiquimod as an Immunologic Adjuvant for NY-ESO-1 Protein Vaccination in Patients with High-Risk Melanoma(2015)91 cited
- → Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial(2012)44 cited
- → Phase II study of low-dose cyclophosphamide and ipilimumab in metastatic melanoma.(2014)5 cited
- → Phase I/II study of resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma.(2012)5 cited
- → Phase I/II study of Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma(2013)4 cited
- → Phase I/II study of the TLR3 agonist poly-ICLC as an adjuvant for NY-ESO-1 protein vaccination with or without Montanide ISA-51 vg in patients with melanoma.(2014)3 cited
- → Poly-ICLC as an adjuvant for NY-ESO-1 protein vaccination with or without Montanide ISA-51 VG in patients with melanoma.(2015)